Manitoba makes LEMTRADA® (alemtuzumab) available to eligible patients with relapsing-remitting MS
21 Jul, 2016, 11:00 ET
Unique treatment delivered in only two cycles one year apart
MISSISSAUGA, ON, July 21, 2016 /CNW/ - Sanofi Genzyme, the specialty care global business unit of Sanofi, is pleased to announce that the Government of Manitoba has added LEMTRADA® (alemtuzumab) to the province's Drug Benefits and Interchangeability Formulary, for eligible patients living with relapsing-remitting multiple sclerosis (RRMS).
Manitoba joins Quebec, Saskatchewan and Ontario in providing the unique treatment to patients 18 years or older who meet specific criteria when prescribed by a neurologist from the Manitoba MS Clinic. The formulary lists therapeutically effective drugs of proven high quality that have been approved as eligible benefits under the Pharmacare drug benefit program.
"I am pleased to see the approval of Lemtrada® for patients in Manitoba - the only agent proven to be more effective than first line treatment for those whose disease was not adequately controlled with prior therapy," says Dr. Mark S. Freedman, Professor of Neurology, University of Ottawa.
"While the ultimate goal of the MS Society of Canada is to find a cure for multiple sclerosis, individuals living with MS need to have access to treatment options to help manage their disease today," says Erin Kuan, President of the MS Society of Canada, Manitoba Division. "We are excited to know there is an important treatment option available when other treatments for Manitobans living with relapsing-remitting MS have not worked. The MS Society of Canada encourages those who might be considering this treatment to consult with their healthcare team."
Approved in Canada in December 2013, LEMTRADA® is indicated for the management of adult patients with RRMS, defined by clinical factors and imaging results, who have had an inadequate response to interferon beta or other disease-modifying therapies.1
LEMTRADA® is delivered in two annual treatment courses, with the first given over five days in year one, and the second over three days in year two. As patients require monitoring at regular intervals between treatment courses and for 48 months following the final infusion, Sanofi Genzyme provides unique, comprehensive and free patient support through its MS One to One™ program.
LEMTRADA® is a monoclonal antibody. Monoclonal antibodies are proteins which bind to a unique site (called an antigen) on cells. LEMTRADA® binds to an antigen, called CD52, which is present at high levels on certain cells of the immune system. LEMTRADA® works on the immune system so that it may not attack the nervous system as much.2 Important and complete safety information about LEMTRADA can be found at: https://www.genzyme.ca/Products.aspx.
The Phase III study CARE MS II showed that, as a second-line treatment, LEMTRADA® is more effective than interferon beta-1a in reducing the annual relapse rate and the time to onset of sustained accumulation of disability.3
"We are very pleased to learn that the province of Manitoba will make LEMTRADA® available to those in Manitoba living with relapsing-remitting MS should they need it," says Peter Brenders, General Manager, Canada, Sanofi Genzyme. "This decision underscores the province's leadership in health care, as this approval acknowledges LEMTRADA®'s transformative potential and capability to have a positive impact on the lives of patients."
About MS in Canada
The Multiple Sclerosis International Federation's 2013 Atlas of MS reported that Canada has the highest rate of MS in the world with 291 cases per 100,000 people, followed by Denmark (227), Sweden (189), Hungary (176), Cyprus (175) and the U.K. (164).4
MS is an autoimmune disease of the central nervous system which attacks myelin, the protective covering of the nerves, causing inflammation and often damaging the myelin. Myelin is necessary for the transmission of nerve impulses through nerve fibres. It is unpredictable and can cause symptoms such as extreme fatigue, lack of coordination, weakness, tingling, impaired sensation, vision problems, bladder problems, cognitive impairment and mood changes. Its effects can be physical, emotional and financial.5
MS can occur at any age, but is usually diagnosed between the ages of 15 to 40, peak years for education, career- and family-building. MS has been diagnosed in children as young as two years old – and in far older adults. MS is three times as likely to occur in women as in men and is more common in people of northern European background.5
About Sanofi – www.sanofi.ca
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. The Sanofi entities in Canada employ close to 1,700 people. In 2015 Sanofi companies invested $133.3 million in R&D in Canada, creating jobs, business and opportunity throughout the country.
Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families. Learn more at www.sanofigenzyme.ca.
LEMTRADA® and Genzyme® are registered trademarks of Genzyme Corporation. Sanofi® is a registered trademark of Sanofi. All rights reserved.
1 LEMTRADA® Product Monograph. Available at https://www.genzyme.ca/Products.aspx
2 LEMTRADA® Consumer Information. Available at https://www.genzyme.ca/Products.aspx
3 Coles AJ et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. The Lancet. 2012 Nov 24;380(9856):1829-39. Available at: www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2961768-1/fulltext. Accessed on June 26, 2016.
4 Multiple Sclerosis International Federation. Atlas of MS. http://www.msif.org/about-us/advocacy/atlas/?gclid=CNjEmKyRx80CFUwvgQodIxAN5A. Accessed June 26, 2016.
5 MS Society of Canada. Who Gets MS. https://mssociety.ca/about-ms/what-is-ms Accessed June 26, 2016.
SOURCE Sanofi Genzyme
For further information: Media Contacts: Robert Tam, Sanofi Canada, 647-271-5011, [email protected]; Catherine R. Cunningham, Sanofi Canada, 514-956-6120, [email protected]; Alyssa Acorn, Cohn & Wolfe, 647-259-3304, [email protected]
Share this article